Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Rhea-AI Summary

Hengrui Pharma (KLRA) reported Q1 2026 revenue of RMB 8.14 billion, up 12.98% YoY, and net profit attributable to shareholders of RMB 2.28 billion, up 21.78% YoY. Innovative drugs generated RMB 4.53 billion, up 25.75% YoY and 61.69% of pharmaceutical sales.

R&D spending was RMB 2.22 billion (~27.32% of revenue). The company recognized RMB 787 million in out-licensing revenue and recorded pipeline progress: 26 clinical trial approvals and 8 NDAs accepted in China. Kailera Therapeutics (NASDAQ: KLRA) completed a Nasdaq listing as a NewCo for GLP-1 assets.

Positive

• Revenue +12.98% to RMB 8.14 billion in Q1 2026
• Net profit +21.78% to RMB 2.28 billion in Q1 2026
• Innovative drugs revenue +25.75% to RMB 4.53 billion (61.69% of pharma sales)
• R&D spend RMB 2.22 billion (~27.32% of revenue)
• Out-licensing revenue RMB 787 million from business development

Negative

• None.

News Market Reaction – KLRA

-3.65%

5 alerts

-3.65% Session close to close

+6.7% Peak in 28 hr 19 min

$3.01B Market Cap

0.3x Rel. Volume

In the Apr 22 session, KLRA declined 3.65%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.7% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlighted Hengrui’s combination of earnings growth and deepening innovation, wit...

Analysis

This announcement highlighted Hengrui’s combination of earnings growth and deepening innovation, with Q1 revenue of RMB 8.14 billion, net profit of RMB 2.28 billion, and RMB 4.53 billion from innovative drugs. Investors may track how the 26 clinical approvals and 8 accepted NDAs translate into future revenue, while monitoring sustained R&D spending of RMB 2.22 billion and progress of the GLP-1 NewCo collaboration.

Key Figures

Q1 2026 revenue: RMB 8.14 billion (+12.98% YoY) Net profit: RMB 2.28 billion (+21.78% YoY) Innovative drug revenue: RMB 4.53 billion (+25.75% YoY) +5 more

8 metrics

Q1 2026 revenue RMB 8.14 billion (+12.98% YoY) Hengrui Pharma Q1 2026 results

Net profit RMB 2.28 billion (+21.78% YoY) Net profit attributable to shareholders, Q1 2026

Innovative drug revenue RMB 4.53 billion (+25.75% YoY) Innovative drugs, Q1 2026

Innovative drug mix 61.69% of pharmaceutical sales Share of total pharmaceutical sales, Q1 2026

R&D investment RMB 2.22 billion (27.32% of revenue) R&D spending in Q1 2026

Clinical trial approvals 26 approvals Pipeline advancement in China, Q1 2026

New drug applications 8 NDAs accepted China, multiple therapeutic areas

Out-licensing revenue RMB 787 million Business development, mainly GSK collaboration, Q1 2026

Key Terms

anti-pd-l1/tgf-βrii bi-functional fusion protein, her2-targeting adc, out-licensing, new drug applications, +1 more

5 terms

anti-pd-l1/tgf-βrii bi-functional fusion protein medical

"included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication"

A lab-made therapeutic protein designed to do two things at once: block a tumor’s “off switch” for immune cells (PD-L1) and soak up a suppressive molecule (TGF-β) that helps tumors hide and grow. Think of it as a two-in-one tool that both releases the brakes on the immune system and clears the surrounding roadblocks so immune cells can reach cancer. Investors watch these drugs because their dual action can affect clinical success, approval chances and commercial potential, but also brings combined efficacy and safety uncertainties.

her2-targeting adc medical

"included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC."

A HER2-targeting ADC is a medicine that combines an antibody programmed to attach to the HER2 protein on certain cancer cells with a potent cell-killing drug, delivered only after the antibody latches on—like a guided missile that releases its payload at the target. For investors, these drugs matter because they can offer more effective cancer control with lower side effects than conventional chemotherapy, influencing clinical success, regulatory approval, market size, and company valuation.

out-licensing financial

"RMB 787 million in out-licensing revenue recognized during the quarter"

Out-licensing is when a company grants another firm the right to develop, manufacture or sell a product or technology in exchange for upfront payments, milestone fees and ongoing royalties. Think of it like leasing a recipe to a larger kitchen so they handle production and sales while the original owner collects steady income and reduces costs and risk. For investors, out-licensing can speed commercialization, create near-term revenue, lower development expenses, and shift where future profits and growth will come from.

new drug applications regulatory

"obtained 26 clinical trial approvals and had 8 new drug applications accepted in China"

New drug applications are formal requests submitted to a medicine regulator asking permission to market a new prescription drug after clinical testing. Think of it as a company presenting proof, like a recipe and test results, to a safety inspector to show the product works and is safe; approval unlocks the ability to sell the drug, while rejection or delay can sharply change a company’s potential revenue and stock value.

glp-1-based medical

"a NewCo company built around Hengrui Pharma's GLP-1-based assets."

Drugs or therapies described as “GLP‑1‑based” are built around a naturally occurring hormone called GLP‑1; they mimic or enhance its action to lower blood sugar and often reduce appetite and weight. Investors watch GLP‑1‑based products because they can drive large sales, change how diseases like diabetes and obesity are treated, and affect regulatory, manufacturing and competitive dynamics — much like a breakthrough engine that can reshape an entire car market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.

The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.

During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.

In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key therapeutic areas including oncology, metabolic, cardiovascular, and immunological diseases.

Business development has become a recurring and increasingly important growth driver, with RMB 787 million in out-licensing revenue recognized during the quarter, primarily from the collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions, including out-licensing, NewCo structures, and strategic alliance models.

A key milestone during the period was the successful Nasdaq listing of Kailera Therapeutics (NASDAQ: KLRA), a NewCo company built around Hengrui Pharma's GLP-1-based assets. This milestone reflects continued progress in executing the Company's NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.

Looking ahead, Hengrui Pharma will remain committed to innovation and globalization, strengthening its pipeline and advancing the development and commercialization of innovative therapies to benefit patients worldwide.

View original content:https://www.prnewswire.com/news-releases/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-profit-growth-302750124.html

SOURCE Hengrui Pharma

FAQ

What were Hengrui Pharma's Q1 2026 revenue and net profit (KLRA)?

Hengrui reported RMB 8.14 billion revenue and RMB 2.28 billion net profit in Q1 2026. According to the company, revenue rose 12.98% YoY and net profit increased 21.78% YoY, driven largely by innovative drug sales and business development revenue.

How much did Hengrui Pharma spend on R&D in Q1 2026 and what percent of revenue was that (KLRA)?

R&D investment was RMB 2.22 billion, representing approximately 27.32% of revenue in Q1 2026. According to the company, this reflects continued emphasis on innovation and pipeline advancement across oncology, metabolic, cardiovascular, and immunological areas.

How did innovative drugs perform for Hengrui Pharma in Q1 2026 (KLRA)?

Innovative drugs generated RMB 4.53 billion, up 25.75% YoY, and accounted for 61.69% of pharmaceutical sales. According to the company, innovative products and new indications approvals helped drive that growth during the quarter.

What business development revenue did Hengrui Pharma report in Q1 2026 and from which collaboration (KLRA)?

The company recognized RMB 787 million in out-licensing revenue during Q1 2026, primarily from the collaboration with GSK. According to the company, business development and NewCo transactions have become a recurring growth driver since 2023.

What pipeline and regulatory milestones did Hengrui Pharma announce in Q1 2026 (KLRA)?

Hengrui obtained 26 clinical trial approvals and had 8 NDAs accepted in China during Q1 2026. According to the company, these actions span oncology, metabolic, cardiovascular, and immunological therapeutic areas and reflect ongoing pipeline progress.